Kornimate/medical-research-clean huggingface dataset:
the stroke vision app: a screening tool for visual stroke

Conditions: Eye Abnormalities; Stroke

Summary: visual impairment can affect up to 70% of stroke survivors, but many do not have their vision adequately assessed in hospital. an unidentified visual defect can cause significant problems for recovery and quality of life. the stroke vision app (an application currently scaled for a 10" android tablet) has been developed to act as a screening tool for visual problems in stroke survivors; to help identify visual problems earlier and thereby improve rehabilitation outcomes. the app includes a suite of tests for assessing the patient's acuity, their visual fields and to aid in the identification of visual neglect / inattention. furthermore, it includes educational information on visual stroke in order to better educate staff, patients and their carers. this study seeks to validate the novel digital assessments included in the stroke vision app against the current methods used for screening (clinical examination by confrontation field testing). both screening measures will be compared with the gold standard methods for visual assessments, octopus perimetry for fields and paper-based methods for visuospatial neglect


Eligibility criteria:
inclusion criteria: * all patients referred to visual stroke orthoptic clinics * all patients with stroke or stroke-like visual problems (for example, but not limited to bitemporal hemianopia caused by pituitary adenoma) referred to the neuro-ophthalmology clinics. * consent provided exclusion criteria: * no spoken english * unable to provide consent * profound cortical blindness
mortality reduction after oral azithromycin: mortality study

Conditions: Childhood Mortality

Summary: our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. we propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo. we hypothesize that mass azithromycin treatments will reduce childhood mortality.

we will assess childhood mortality over three years, comparing communities where children aged 1-60 months receive biannual oral azithromycin ("azithromycin" arm) for two years, to communities where the children receive biannual oral placebo ("control" arm) for two years. during the third year at the niger site only, everyone will receive azithromycin. this is a cluster-randomized trial; at each site, communities within a contiguous area of 300,000 to 600,000 individuals will be randomized to azithromycin or placebo using simple random sampling. niger contingency study: in the event that mass distributions of oral azithromycin are proven to reduce mortality in 1-60 month-old children, then we will treat all communities in niger with mass azithromycin distributions to test whether the intervention continues to reduce childhood mortality after the initial 2 years of mass treatments.

Eligibility criteria:
inclusion criteria: communities * the community location in target district. * the community leader consents to participation in the trial * the community's estimated population is between 200-2,000 people. * the community is not in an urban area. individuals - all children aged 1-60 months (up to but not including the 5th birthday), as assessed via biannual census. exclusion criteria: individuals - refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)

Keywords: childhood mortality azithromycin mass treatment infection verbal autopsy
an efficacy study of teriflunomide in participants with relapsing multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the primary objective of the study was to assess the effect of two doses of teriflunomide, in comparison to placebo, on the frequency of multiple sclerosis (ms) relapses in participants with relapsing ms. key secondary objective was to assess the effect of the two doses of teriflunomide, in comparison to placebo, on disability progression. other secondary objectives were: * to assess the effect of the two doses of teriflunomide in comparison to placebo on: * fatigue; * health-related quality of life, a measure of the impact of the participant's health on his or her overall well being. * to evaluate the safety and tolerability of teriflunomide.

the study consists of: * a core treatment period: teriflunomide 7 mg or teriflunomide 14 mg or placebo was administered in double-blind fashion until a fixed common end date which was approximately 48 weeks after randomization of the last participant. * an extension treatment period: the highest dose of teriflunomide was administered in open-label fashion to participants who successfully complete the core treatment period and wish to continue. the overall treatment period was followed by a 4-week elimination follow-up period.

Eligibility criteria:
inclusion criteria: * relapsing multiple sclerosis, * two relapses in prior 2 years or one relapse in prior year. exclusion criteria: * clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease, * significantly impaired bone marrow function or, significant anemia, leukopenia or thrombocytopenia, * pregnant or nursing woman, * alcohol or drug abuse, * prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate, * human immunodeficiency virus (hiv) positive, * any known condition or circumstance that would prevent, in the investigator's opinion, compliance or completion of the study. the above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Keywords: relapsing multiple sclerosis
enumeration and function analysis of treg cells in peripheral blood of hcc patients before and after ablation therapy

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to determine the enumeration and function changes of regulatory t cells in peripheral blood of hepatocellular carcinoma patients before and 1 week, 4 weeks after ablation therapy.

regulatory t cells，which are also called treg cells，play an important role in suppressing anti-tumor immunity.accumulated evidences indicate that treg cells are elevated in peripheral blood,however,there are also reports that decreased treg cells are found in hepatocellular patients.this study focuses on the changes of treg cells ratio in peripheral blood of hepatocellular carcinoma patients before and 1 week, 4 weeks after ablation ,also its functional cytokines,such as tgf-β,il-10,ifn-γ,and inhibition function when co-cultured with cd4+cd25-、cd8+ cells. the investigators speculate that a decreased treg ratio will be found in patients who receive ablation therapy,and its function cytokines,moreover,cd4+cd25-、cd8+ cells' proliferation and function could be inhibited when co-cultured with treg cells.

Eligibility criteria:
inclusion criteria: * hepatocellular patients diagnosed through biopsy;or either dynamic imagine with a diagnosis of hepatocellular carcinoma and alphafetoprotein\>400μg/l；or two or more dynamic imagine with a diagnosis of hepatocellular carcinoma * child-pugh a or b * well preserved renal and hematopoietic function * receive ablation therapy through percutaneous radiofrequency ablation or microwave ablation or ethanol injection ablation or any kind of combination of them. * achieve complete ablation accessed by contrast-enhanced ct exclusion criteria: * incomplete ablation * remote metastasis * child-pugh c * general infection * autoimmune diseases * suffer from other tumors concurrently or in last five years * patients with immune deficit or infected by hiv * receiving glucocorticoid or other medicine inhibiting immune system

Keywords: hepatocellular carcinoma catheter ablation t-lymphocytes, regulatory il-10 tgf-β ifn-γ
il1rap-targeting chimeric antigen receptor t cells in the treatment of relapsed/refractory hepatocellular carcinoma

Conditions: HCC

Summary: a phase 1 study of il1rap-targeting chimeric antigen receptor t cells in the treatment of relapsed/refractory hepatocellular carcinoma


Eligibility criteria:
inclusion criteria: 1. age 18-70 years old, male or female; 2. patients with advanced hepatocellular carcinoma who are confirmed by histopathology and/or cytology to be ineligible for surgery and local radical therapy and who have developed tumor progression or toxicity intolerance following at least one standardized systemic therapy (including molecularly targeted agents and immune checkpoint inhibitors) or interventional therapy 3. liver cancer subjects with stage ii or iii of china liver cancer staging (cnlc) as defined by barcelona clinic liver cancer (bclc) b/c level or the code of practice for primary liver cancer diagnosis and treatment (2022 edition); 4. expected survival ≥3 months 5. before the start of the research related procedures, after explaining the research content, voluntarily participate and be able to sign the informed consent; agree to and have the ability to follow study visits, imaging tests, laboratory tests, and other research procedures in the study plan; 6. good compliance, willing and able to follow all research procedures, and cooperate with observation and follow-up. exclusion criteria: 1. have had other uncured malignancies within the past 5 years or at the same time, except for in situ cancers considered clinically curable, such as cervical carcinoma in situ and basal cell carcinoma of the skin 2. central nervous system metastases and clinically significant central nervous system diseases 3. pregnant or lactating women; 4. the investigator believes that the subjects have any circumstances that make them unfit to participate in this clinical study.
real-world study of dedifferentiated liposarcoma patients in china

Conditions: Dedifferentiated Liposarcoma

Summary: this study will characterize patients with dedifferentiated liposarcoma (ddlps) in china, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.


Eligibility criteria:
inclusion criteria: * patient has two or more documented clinical visits in the national anti-tumor drug surveillance system (natdss) network on or after january 1, 2013. * patient has a confirmed diagnosis of dedifferentiated liposarcoma (ddlps) during his/her lifetime. * at least 18 years old at the date of initial diagnosis. no exclusion criteria are applied.
intravesical gentamicin to prevent recurrent uti

Conditions: Recurrent Uti

Summary: feasibility assessment of intravesical gentamicin instillation (putting antibiotics directly into the bladder) versus the current standard of care of oral nitrofurantoin prophylaxis (taking a low dose of antibiotics by mouth every day) to prevent recurrent urinary tract infections (uti)

the overall goal of this project is to assess the feasibility of a larger trial investigating the use of intravesical gentamicin instillation (putting antibiotics directly into the bladder) versus the current standard of care of oral nitrofurantoin prophylaxis (taking a low dose of antibiotics by mouth every day). investigators plan to gain patient perspective regarding preferences for study design and assess associations between the treatments with changes in the postmenopausal urinary microbiome (urobiome).

Eligibility criteria:
inclusion criteria: * postmenopausal * 2 utis in 6 months * desire to start antibiotic prophylaxis to prevent utis exclusion criteria: * parkinsons disease * myasthenia gravis * renal failure * liver failure * bladder pain syndrome * multiple negative urine cultures associated with uti symptoms (\>/= 3) * bladder botox treatments in the past * treatment planned for ui and prolapse * unevaluated microscopic hematuria * history of kidney stones * no antibiotics within 4 weeks * most recent weight \<40kg (88.18lbs) * surgically altered urinary tract (urinary diversion, phalloplasty, etc) * allergy or hypersensitivity to either of the study medications or medications in the same family including but not limited to: amikacin, kanamycin, neomycin, paromomycin, streptomycin, tobramycin.
an exploratory study of effectiveness and safety of rivaroxaban in patients with left ventricular thrombus (r-dissolve)

Conditions: Ventricular Mural Thrombosis

Summary: to study the effect of rivaroxaban anticoagulant therapy for 12 weeks in patients with left ventricular mural thrombus by contrast echocardiography before and after treatment, so as to provide basis and foundation for further study and treatment selection in the future; to provide further relevant data for the treatment outcome, treatment duration and influencing factors of left ventricular mural thrombosis; it is of great sociological and health economic significance to find more effective and safe anticoagulant treatment strategies for patients with left ventricular mural thrombosis, which will reduce the incidence of embolism and bleeding.


Eligibility criteria:
inclusion criteria: 1. patients over 18 years old; 2. patients with left ventricular thrombus newly found by body surface ultrasound less than or equal to 3 months before selection, with no limitation on basic diseases; 3. patients who received standard anticoagulant therapy for less than 4 weeks before enrollment did not use antiplatelet drugs or only used single antiplatelet drugs; 4. the patients voluntarily joined the study and signed the informed consent. exclusion criteria: 1. patients with contraindications to rivaroxaban anticoagulation therapy; 2. patients with a history of acute pulmonary embolism or deep venous thrombosis within a week need intensive anticoagulant therapy; 3. patients with history of hemorrhagic stroke within one week; 4. patients with cardiac benign and malignant tumors; 5. aspirin and p2y12 receptor antagonists should be kept; 6. in patients with severe hepatic and renal insufficiency, alanine aminotransferase \> 3 times the upper limit and total bilirubin \> 2 times the upper limit, creatinine clearance rate \< 15ml / min / 1.73m2; 7. the patient's history of intracerebral hemorrhage and active hemorrhage was 8 months; 8. patients with hematological diseases, hemoglobin \< 100g / l, platelet \< 80 x 10\^9 / l; 9. women with pregnancy status, planned pregnancy and lactation period; 10. patients with life expectancy less than 1 year; 11. patients enrolled in other clinical studies; 12. other situations considered unsuitable by the researcher. note: anticoagulant therapy can be given to patients with left ventricular thrombosis combined with hemorrhagic stroke ≥ 4 weeks or recent ischemic stroke / transient ischemic attack according to the specific situation.
surveillance study to assess the safety of flublok quadrivalent (influenza vaccine) in pregnant women and their offspring

Conditions: Influenza

Summary: primary objective: to evaluate the safety of flublok quadrivalent influenza vaccine in pregnant women included in the vap00003 study (nct03694392) and their offspring exposed during pregnancy or up to 28 days preceding the estimated date of conception with regards to pregnancy, birth, and neonatal/infant outcomes secondary objective:

data will be recorded prospectively during the safety follow-up for pregnant women until delivery (or pregnancy outcome, whichever is later), and for infants of pregnant women for 1 year after birth.

Eligibility criteria:
inclusion criteria pregnant women: * laboratory or medical professional confirmation of pregnancy * exposure to either flublok quadrivalent influenza vaccine or standard-dose quadrivalent inactivated influenza vaccine (sd-iiv4) in the vap00003 study during pregnancy or within 28 days preceding conception offspring: * infants delivered by pregnant women who satisfy the criteria above exclusion criteria * documented receipt of any other influenza vaccine at any other time during the pregnancy the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
ngs vs culture outcomes for treatment of pji

Conditions: Prosthetic Joint Infection

Summary: this multicenter, randomized controlled trial will compare the use of ngs and traditional culture in directing antimicrobial treatment for patients with periprosthetic joint infection.


Eligibility criteria:
inclusion criteria: * adults (age \> 18 years) * undergoing single stage revision or 1st stage resection arthroplasty/spacer placement for pji (icm-positive) of the hip or knee * written informed consent exclusion criteria: * ongoing participation in another clinical trial * megaprosthesis
neopterin dosage in the eye

Conditions: Cataract

Summary: the purpose of the study is to determine whether neopterin can be dosed in the fluid of the eye's anterior chamber for patient with non-inflammatory and non-infectious ophthalmic pathology.

the study will be explained to subjects who are about to undergo ophthalmologic surgery. they will sign an informed consent and be included in the study. urine sample will be collected specifically for the study. eye's anterior chamber fluid will also be collected during the surgery as it is the usual practice (the sample is used for the neopterin dosage instead of being thrown away). these samples will be centrifuged, frozen in a -80° c freezer. at the end of the study, all the samples will be sent to the central lab for the neopterin dosage analysis. results will be communicated to the principal investigator afterward.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years-old * non inflammatory or non infectious ophthalmic pathology requiring puncture of eye's anterior chamber fluid. * minimum of 200 microliter sample * immunocompetent subjects * signed and dated informed consent * samples management in accordance with the pre-analytical conditions specified in the protocol non-inclusion criteria: * age \< 18 years-old * subjects treated with intraocular corticoids, antibiotics or anti-inflammatory, locally or in systemic injection, prior to inclusion. exclusion criteria: * subjects who exercised his right of withdrawal * study suspended on principal investigator, sponsor or health authorities' demand. * deceased subjects

Keywords: eye's anterior chamber fluid cerebrospinal fluid inflammatory pathology
gene-environment-interaction: influence of the comt genotype on the effects of different cannabinoids

Conditions: Healthy; Modeling Psychosis

Summary: the study evaluates the gene-environment interaction of the comt-genotype on the effects of the phytocannabinoids delta-9-tetrahydrocannabinol, cannabidiol or a combination of both on induction of psychotic symptoms, endocannabinoid levels in human body fluids, neuronal processing, and neural oscillations. in addition the effects of the phytocannabinoids on lipid levels in serum and cerebrospinal fluid, cognition, neural synchrony and neuronal processing assessed by eeg and fmri.


Eligibility criteria:
inclusion criteria: * informed consent given by the subject * healthy young man (age between 18 and 45) insightful to the study (wst\> 95) * right handedness * at least one time consumption of cannabis but less than 10 times/ per lifetime, no consumption of other psychotropic agents (despite coffee or nicotine), no alcohol abuse * negative drug-screening at the time of screening * body mass index between 18 and 30 exclusion criteria: * lack of accountability * participation in other interventional trials * severe medical or neurological illness, especially cardiovascular, renal, advanced respiratory, hematological or endocrinological failures or infectious diseases (acute hepatitis a, b or c or hiv) assessed at the time of the screening by the subject's history, clinical examination and laboratory testing, at the discretion of the investigator * any known psychiatric illness in the participant's history * known family history concerning psychiatric disorders * cannabis consumption within the last six months * consumption of any illegal drugs (except cannabis in history, see above) * intake of interfering medication, at the discretion of the investigator * high intracranial pressure * any disorders in stereoscopic vision (measured by the tno-test, lamerics, utrecht) or hearing deficits * contraindications due to the investigators brochure contraindication for magnetic resonance imaging (e.g. cardiac pacemaker, claustrophobia, attached brace, in body metal, tattoos) or lumbar puncture (e.g. local or systemic infection, disturbance of blood coagulation, medication with anticoagulants like phenprocoumon)

Keywords: delta-9-tetrahydrocannabinol cannabidiol comt volunteers
nutritional strategy for blood pressure control in patients with hypertension (nupress)

Conditions: Hypertension

Summary: adherence to a healthy dietary pattern is part of the self-care of patients with hypertension, and may contribute substantially to therapeutic target goals as well as to a better quality of life. however, not all nutritional recommendations aimed at these patients are easily applicable in clinical practice. the primary objective of the study is to evaluate the effectiveness of a nutritional strategy for blood pressure control in patients with hypertension users of a public health system after 6 months of follow-up. as secondary objectives, we will evaluate the impact of the proposed strategy on self-care and on the quality of life of the patients. in this multicenter open-label randomized trial, 408 patients ≥21 years old with hypertension, systolic blood pressure (sbp) ≥140mmhg at the moment of the screening and who have not received or received nutritional counseling for at least 06 months will be enrolled. patients allocated to the control group will receive individualized dietary prescription according to the guidelines of the brazilian society of cardiology. nutritional counseling in the intervention group will be performed based on the quality of the diet, the food guide for the brazilian population and concepts of mindfulness and mindful eating; all dietary guidance will be based on feasible goals built together (patient and nutritionist), and no diet will be prescribed for intervention group. in both groups, patients will receive automatic monitors for residential self-monitoring blood pressure. on-site follow-up visits will be carried out at 30, 60, 90, and 180 days (final consultation). at 120 and 150 days, participants in the intervention group will receive motivational messages via e-mail or sms (for these patients, consultation of 30 days will be a group meeting). laboratory tests (lipid and glycemic profile, serum creatinine, serum sodium, urinary sodium, serum potassium, urinary potassium and albuminuria) will be performed at baseline and 180 days; anthropometric indexes and diastolic blood pressure (dbp) will be also evaluated.


Eligibility criteria:
inclusion criteria: ≥21 years old with medical diagnosis of hypertension, systolic blood pressure (sbp) ≥140 mmhg at the moment of the screening and who have not received or received nutritional counseling for at least 06 months. exclusion criteria: * diagnosis of resistant and/or secondary hypertension; * severe neuropathy; * chronic kidney disease; * active cancer or life expectancy \<6 months; * chemical dependence or use of antipsychotic drugs; * autoimmune disease or chronic use of steroids; * pregnancy and lactation; * acute coronary syndrome in the last 60 days; * severe or unstable heart failure; * wheelchair users; * extreme obesity (body mass index \[bmi\] ≥40kg / m²); * cognitive, neurological or psychiatric condition that prevents participation in the study; * participation in other clinical trials.